US Broker Ratings

Artivion, Inc. (AORT) Investor Outlook: Navigating High Valuation and Growth Dynamics in the Medical Device Sector

Artivion, Inc. (AORT), a forward-thinking player in the medical device industry, has been attracting considerable attention within the healthcare sector. With a market capitalization of $2.02 billion, Artivion is well-positioned..

U.S. Physical Therapy, Inc. (USPH) Stock Analysis: Exploring a 26.78% Potential Upside

U.S. Physical Therapy, Inc. (NYSE: USPH), a prominent player in the healthcare sector, is catching the attention of investors with a compelling growth narrative and an impressive 26.78% potential upside...

Phreesia, Inc. (PHR) Stock Analysis: Strong Buy Ratings and 10.7% Upside Potential

Phreesia, Inc. (NASDAQ: PHR), a leader in the healthcare information services sector, has been making waves with its innovative SaaS-based software and payment platform designed to streamline the healthcare experience...

Mineralys Therapeutics, Inc. (MLYS) Investor Outlook: Exploring a 136% Potential Upside

For investors eyeing the biotechnology sector, Mineralys Therapeutics, Inc. (NASDAQ: MLYS) presents a compelling opportunity, particularly given its substantial potential upside. Based in Radnor, Pennsylvania, this clinical-stage biopharmaceutical company is..

Immunocore Holdings plc (IMCR) Stock Analysis: Exploring a Bold 91.88% Potential Upside

Immunocore Holdings plc (NASDAQ: IMCR), a prominent player within the biotechnology industry, is garnering significant attention from investors due to its promising pipeline and an eye-catching potential upside of 91.88%...

AtriCure, Inc. (ATRC) Stock Analysis: Exploring a 40% Upside Potential Driven by Strong Analyst Support

AtriCure, Inc. (NASDAQ: ATRC), a prominent player in the healthcare sector, is attracting attention with a notable potential upside of 40.37%, according to recent analyst ratings. Specializing in medical instruments..

89bio, Inc. (ETNB) Investor Outlook: Exploring a Potential 210% Upside in the Biotech Sector

89bio, Inc. (ETNB) is capturing the attention of investors with its promising potential upside of 210.09%, as indicated by analyst ratings. This clinical-stage biopharmaceutical company, headquartered in San Francisco, is..

Ocular Therapeutix, Inc. (OCUL) Stock Analysis: A Biotech Play with 41.79% Upside Potential

Ocular Therapeutix, Inc. (NASDAQ: OCUL) is garnering attention in the biotechnology sector, especially among investors seeking high-risk, high-reward opportunities. Based in Bedford, Massachusetts, Ocular Therapeutix focuses on developing and commercializing..

Pediatrix Medical Group, Inc. (MD) Stock Analysis: Strong Potential with a Forward P/E of 8.68 and a 4.46% Upside

Pediatrix Medical Group, Inc. (NYSE: MD), a prominent player in the healthcare sector, primarily focuses on providing neonatal and pediatric care across the United States. With a market capitalization of..

Vera Therapeutics, Inc. (VERA) Stock Analysis: Assessing a Potential 192% Upside in the Biotechnology Sector

Vera Therapeutics, Inc. (NASDAQ: VERA), a prominent player in the biotechnology sector, has been garnering significant attention from investors seeking high-growth opportunities within the healthcare industry. With its market capitalization..

Centessa Pharmaceuticals (CNTA) Stock Analysis: An 84.45% Potential Upside Amid Strong Buy Ratings

Centessa Pharmaceuticals plc (NASDAQ: CNTA), a biotechnology company based in the United Kingdom, has captured investor attention with its promising pipeline and a significant potential upside of 84.45%. With a..

Tarsus Pharmaceuticals, Inc. (TARS) Stock Analysis: Exploring a 39% Upside Potential in Biotechnology

Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), a promising player in the biotechnology sector, has captured the attention of investors with a striking 39.17% potential upside. As a commercial-stage biopharmaceutical company, Tarsus..

Ligand Pharmaceuticals (LGND): Investor Outlook with Strong Buy Ratings and Growth Potential

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND), a prominent player in the biotechnology sector, presents a compelling case for investors seeking exposure to the healthcare industry. With a market capitalization of $3.02..

AdaptHealth Corp. (AHCO) Stock Analysis: Unlocking a 39.93% Potential Upside with Strategic Healthcare Solutions

AdaptHealth Corp. (NASDAQ: AHCO), a dynamic player in the healthcare sector specializing in medical devices, is attracting attention within the investment community. With a robust market capitalization of $1.27 billion,..

Progyny, Inc. (PGNY) Investor Outlook: Navigating Fertility Solutions with 16.69% Upside Potential

Progyny, Inc. (NASDAQ: PGNY) stands at the forefront of the healthcare plans industry, delivering innovative fertility and family-building solutions across the United States. With a market capitalization of $2.04 billion,..

Teladoc Health, Inc. (TDOC) Stock Analysis: Navigating Healthcare’s Digital Frontier with a Potential 21.83% Upside

Teladoc Health, Inc. (NYSE: TDOC) stands at the forefront of the digital healthcare revolution, a sector whose relevance skyrocketed during the global pandemic. As the leading provider of virtual healthcare..

Arcutis Biotherapeutics, Inc. (ARQT): Investor Outlook on Its Promising 30.57% Upside Potential

Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) is drawing attention from investors eager to capitalize on its promising growth in the healthcare sector, specifically within biotechnology. With a current market capitalization of..

Schrodinger, Inc. (SDGR) Stock Analysis: Potential Upside of 40.76% Captivates Investor Interest

Schrodinger, Inc. (NASDAQ: SDGR), a leader in the healthcare sector’s dynamic health information services industry, offers an intriguing proposition for investors seeking opportunities with substantial upside potential. With a market..

MiMedx Group, Inc. (MDXG) Stock Analysis: Exploring a 69.68% Potential Upside in Biotechnology

Investors with a keen eye on the healthcare sector might find MiMedx Group, Inc. (NASDAQ: MDXG) a compelling opportunity, especially considering the significant potential upside of 69.68% as indicated by..

Recursion Pharmaceuticals, Inc. (RXRX) Stock Analysis: Decoding the 17.15% Potential Upside for Investors

Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) operates at the intriguing intersection of biotechnology and technology, making waves in the healthcare sector with its innovative approach to drug discovery. With a focus..

US Broker Ratings

US Broker Ratings

FTSE 100

Funds